TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Código QR

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations

Madhu M Ouseph,1 Angela Taber,2 Humera Khurshid,3 Russell Madison,4 Bassam I Aswad,1 Murray B Resnick,1 Evgeny Yakirevich,1 Siraj M Ali,4 Nimesh R Patel11Department of Pathology, Rhode Island Hospital and Alpert Medical School at Brown University, Providence, RI 02903, USA; 2Division of Medical Onco...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Cancer Genomics Profiling Beta-catenin Resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/b29f4543d9f24599a60ac71423440ff6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
por: Schrock AB, et al.
Publicado: (2020)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
por: Marianne Oulhen, et al.
Publicado: (2021)

ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Sebastian Y. F. Michels, et al.
Publicado: (2017)

Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
por: Deng L, et al.
Publicado: (2018)

ALK rearranged non–small cell lung carcinoma with EML4-NTRK3 fusion as a possible mechanism of resistance to third-generation ALK inhibitors
por: Elena Corral de la Fuente, et al.
Publicado: (2021)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Targeted inhibition in tumors with ALK dependency
por: Kwak EL, et al.
Publicado: (2013)

Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021)

Efficacy and Drug Resistance Analysis of ALK Inhibitors in Combination with Stereotactic Body Radiation Therapy for Treating Lung Squamous Carcinoma Patient Harboring EML4-ALK Rearrangement
por: Liang L, et al.
Publicado: (2021)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Hayato Mizuta, et al.
Publicado: (2021)

Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
por: Umberto Caterino, et al.
Publicado: (2021)

Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials
por: Hao-chuan Ma, et al.
Publicado: (2021)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns MW, et al.
Publicado: (2015)

Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
por: Zhu VW, et al.
Publicado: (2020)

Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
por: Zhu VW, et al.
Publicado: (2018)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi S, et al.
Publicado: (2015)

New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
por: Weise AM, et al.
Publicado: (2014)

Genomic and experimental evidence that ALKATI does not predict single agent sensitivity to ALK inhibitors
por: Haider Inam, et al.
Publicado: (2021)

The Dual Effect of the BMP9–ALK1 Pathway in Blood Vessels: An Opportunity for Cancer Therapy Improvement?
por: Blanca Ayuso-Íñigo, et al.
Publicado: (2021)

Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
por: Berghmans T, et al.
Publicado: (2012)

Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
por: Yi-Lin Chen, et al.
Publicado: (2021)

LncRNA CASC11 promotes the cervical cancer progression by activating Wnt/beta-catenin signaling pathway
por: Hsu,Wenchan, et al.
Publicado: (2019)

Manejo clínico y terapéutico de un tumor fibroso pleural con translocación de ALK
por: Patricia Cruz-Castellanos, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

β-Catenin: oncogenic role and therapeutic target in cervical cancer
por: Wang,Bingqi, et al.
Publicado: (2020)

Non-secretory multiple myeloma with unusual TFG-ALK fusion showed dramatic response to ALK inhibition
por: Ashiq Masood, et al.
Publicado: (2021)

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
por: Daugrois Camille, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

miR-142-5p promotes cervical cancer progression by targeting LMX1A through Wnt/β-catenin pathway
por: Ke Lijuan, et al.
Publicado: (2021)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Tomohiro Enokida, et al.
Publicado: (2021)

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
por: Jain RK, et al.
Publicado: (2017)

Brigatinib treated ALK positive lung squamous cell carcinoma after failed chemotherapy: A case report
por: Shuluan Li, et al.
Publicado: (2021)

Expresión inmunohistoquímica del complejo E-caderina-catenina en cáncer gástrico: Relación con variables clínico-morfológicas y sobrevida de pacientes
por: Guzmán G,Pablo, et al.
Publicado: (2006)

ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells
por: Anna M. Schläfli, et al.
Publicado: (2021)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
por: Takahiro Tsuji, et al.
Publicado: (2020)

A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.
por: Kazuya Takamochi, et al.
Publicado: (2013)

Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities
por: Sharanya Maanasi Kalasekar, et al.
Publicado: (2021)

Novel lncRNA LINC01614 Facilitates Bladder Cancer Proliferation, Migration and Invasion Through the miR-217/RUNX2/Wnt/β-Catenin Axis
por: Wang Z, et al.
Publicado: (2021)

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
por: Giroux Leprieur E, et al.
Publicado: (2016)